• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by SpringWorks Therapeutics Inc.

    2/20/25 7:01:06 AM ET
    $SWTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SWTX alert in real time by email
    S-8 1 tm256973d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on February 20, 2025

    Registration No. 333-     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    Under

    The Securities Act of 1933

     

    SPRINGWORKS THERAPEUTICS, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   83-4066827
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification Number)
         
    100 Washington Blvd
    Stamford, CT
      06902
    (Address of Principal Executive Offices)   (Zip Code)

     

    SpringWorks Therapeutics, Inc. Amended and Restated 2019 Stock Option and Equity Incentive Plan

    SpringWorks Therapeutics, Inc. 2019 Employee Stock Purchase Plan

    (Full Title of the plans)

     

     

    Saqib Islam
    Chief Executive Officer
    100 Washington Blvd
    Stamford, CT 06902

    (Name and address for agent for service)

     

     

    (203) 883-9490

    (Telephone number, including area code, of agent for service)

     

     

    Copies to:

    Kingsley Taft

    Sarah Ashfaq

    Goodwin Procter LLP

    100 Northern Avenue

    Boston, Massachusetts 02210

    (617) 570-1000

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer  x   Accelerated filer  ¨
    Non-accelerated filer  ¨   Smaller reporting company  ¨
        Emerging growth company  ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 registers additional shares of the Registrant’s common stock, par value $0.0001 (the “Common Stock”) under the Registrant’s Amended and Restated 2019 Stock Option and Equity Incentive Plan (the “Equity Incentive Plan”) and 2019 Employee Stock Purchase Plan (the “ESPP”).

     

    The number of shares of Common Stock reserved and available for issuance under the Equity Incentive Plan is subject to an automatic annual increase on each January 1, by an amount equal to 5% percent of the number of shares of Common Stock issued and outstanding on the immediately preceding December 31 or such lesser number of shares of Common Stock as determined by the Administrator of the Equity Incentive Plan (as defined in the Equity Incentive Plan). Accordingly, on January 1, 2025, the number of shares of Common Stock reserved and available for issuance under the Equity Incentive Plan increased by 3,720,163 shares.

     

    The number of shares of Common Stock reserved and available for issuance under the ESPP is subject to an automatic annual increase on each January 1, by the lesser of (i) 1% of the outstanding shares on the immediately preceding December 31, (ii) 663,229 shares of Common Stock, or (iii) such amount as determined by the Administrator of the ESPP (as defined in the ESPP). Accordingly, on January 1, 2025, the number of shares of Common Stock reserved and available for issuance under the ESPP increased by 663,229 shares.

     

    This Registration Statement on Form S-8 registers these additional 4,383,392 shares of Common Stock. The additional shares are of the same class as other securities relating to the plans for which the Registrant’s registration statements filed on Form S-8 on October 29, 2019 (Registration No. 333-234365), March 23, 2020 (Registration No. 333-237350), February 25, 2021 (Registration No. 333-253531), February 24, 2022 (Registration No. 333-262996), February 28, 2023 (Registration No. 333-270096) and February 27, 2024 (Registration No. 333-277380) are effective. The information contained in the Registrant’s registration statement on Form S-8 on October 29, 2019 (Registration No. 333-234365), March 23, 2020 (Registration No. 333-237350), February 25, 2021 (Registration No. 333-253531), February 24, 2022 (Registration No. 333-262996), February 28, 2023 (Registration No. 333-270096) and February 27, 2024 (Registration No. 333-277380) are hereby incorporated by reference pursuant to General Instruction E.

     

    Part II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 8. Exhibits.

     

    See the Exhibit Index on the page immediately preceding the exhibits for a list of exhibits filed as part of this Registration Statement, which Exhibit Index is incorporated herein by reference.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Stamford, Connecticut on the 20th day of February, 2025.

     

    SPRINGWORKS THERAPEUTICS, INC.  
         
    By: /s/ Saqib Islam  
      Saqib Islam, J.D.  
      Chief Executive Officer and Director  

     

    POWER OF ATTORNEY AND SIGNATURES

     

    KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints each of Saqib Islam and Francis I. Perier, Jr. as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following person in the capacities and on the date indicated.

     

    Name   Title   Date
             
    /s/ Saqib Islam   Chief Executive Officer, Director   February 20, 2025
    Saqib Islam, J.D.   (Principal Executive Officer)    
             
    /s/ Francis I. Perier, Jr.   Chief Financial Officer   February 20, 2025
    Francis I. Perier, Jr.   (Principal Financial Officer)    
             
    /s/Michael P. Nofi   Chief Accounting Officer   February 20, 2025
    Michael P. Nofi   (Principal Accounting Officer)    
             
    /s/ Daniel S. Lynch   Chairman   February 20, 2025
    Daniel S. Lynch, M.B.A.        
             
    s/ Carlos Albán   Director   February 20, 2025
    Carlos Albán        
             
    /s/ Alan Fuhrman   Director   February 20, 2025
    Alan Fuhrman        
             
    /s/ Julie Hambleton    Director   February 20, 2025
    Julie Hambleton, M.D.        
             
    /s/ Freda Lewis-Hall   Director   February 20, 2025
    Freda Lewis-Hall, M.D., DFAPA        
             

    /s/ Martin Mackay

      Director   February 20, 2025
    Martin Mackay, Ph.D.        

     

     

     

     

    EXHIBIT INDEX

     

    Exhibit
    No.
      Description
    4.1   Second Amended and Restated Certificate of Incorporation of SpringWorks Therapeutics, Inc. (Incorporated by reference to Exhibit 3.1 to the Registrant’s Form 8-K, filed with the Securities and Exchange Commission on September 17, 2019 (File No. 001-39044)).
    4.2   Amended and Restated Bylaws of the registrant, as currently in effect. (Incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on September 17, 2019 (File No. 001-39044)).
    4.3   Amendment to the Amended and Restated Bylaws of the Registrant, as currently in effect. (Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 27, 2020 (File No. 001-39044).
    4.4   Amended and Restated Investors’ Rights Agreement by and among the Registrant and certain of its stockholders, dated August 30, 2019 (Incorporated by reference to Exhibit 4.2 to the Registrant’s Registration Statement on Form S-1, as amended, filed with the Securities and Exchange Commission on September 3, 2019 (File No. 333-233351)).
    4.5   Amendment to the Amended and Restated Investors’ Rights Agreement, dated as of February 25, 2021 (Incorporated by reference to Exhibit 4.4 to the Registrant's Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 25, 2021 (File No. 001-39044)).
    4.6   Description of the Registrant’s Securities (Incorporated by reference to Exhibit 4.3 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission on February 27, 2024 (File No. 001-39044)).
    5.1*   Opinion of Goodwin Procter LLP.
    23.1*   Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm.
    23.2*   Consent of Goodwin Procter LLP (included in Exhibit 5.1).
    24.1*   Power of Attorney (included on signature page).
    99.1   Amended and Restated 2019 Stock Option and Equity Incentive Plan and forms of award agreements thereunder (Incorporated by reference to Exhibit 10.2 to the Registrant’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 24, 2022 (File No. 001-39044)).
    99.2   2019 Employee Stock Purchase Plan (Incorporated by reference to Exhibit 10.3 to the Registrant’s Registration Statement on Form S-1, as amended, filed on September 3, 2019  (File No. 333-233351)).
    107*   Filing Fee Table.

     

    *   Filed herewith.

     

     

     

    Get the next $SWTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SWTX

    DatePrice TargetRatingAnalyst
    11/20/2024$60.00Outperform
    Evercore ISI
    2/5/2024$75.00Buy
    Guggenheim
    12/1/2022$45.00Buy
    BofA Securities
    9/8/2021$97.00 → $105.00Overweight
    JP Morgan
    8/5/2021$136.00 → $137.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $SWTX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 27, 2023 - FDA Approves First Therapy for Rare Type of Non-Cancerous Tumors

    For Immediate Release: November 27, 2023 Today, the U.S. Food and Drug Administration approved Ogsiveo (nirogacestat) tablets for adult patients with progressing desmoid tumors who require systemic treatment. Ogsiveo is the first drug to be approved for the treatment of patients with desmoid tumors, a rare subtype of soft tissue sarcomas. Desmoid tumors are non-cancerous but can be locally aggressive. The tumor

    11/27/23 5:34:21 PM ET
    $SWTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for OGSIVEO issued to SPRINGWORKS THERAPEUTICS INC

    Submission status for SPRINGWORKS THERAPEUTICS INC's drug OGSIVEO (ORIG-1) with active ingredient NIROGACESTAT has changed to 'Approval' on 11/27/2023. Application Category: NDA, Application Number: 217677, Application Classification: Type 1 - New Molecular Entity

    11/27/23 5:34:04 PM ET
    $SWTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SWTX
    SEC Filings

    View All

    SEC Form 15-12G filed by SpringWorks Therapeutics Inc.

    15-12G - SpringWorks Therapeutics, Inc. (0001773427) (Filer)

    7/11/25 6:00:19 AM ET
    $SWTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SCHEDULE 13G filed by SpringWorks Therapeutics Inc.

    SCHEDULE 13G - SpringWorks Therapeutics, Inc. (0001773427) (Subject)

    7/7/25 4:04:19 PM ET
    $SWTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 POS filed by SpringWorks Therapeutics Inc.

    S-8 POS - SpringWorks Therapeutics, Inc. (0001773427) (Filer)

    7/1/25 4:11:31 PM ET
    $SWTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SWTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology

    STAMFORD, Conn., Oct. 21, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that long-term efficacy and safety data from the Phase 3 DeFi trial of OGSIVEO® (nirogacestat), an oral gamma secretase inhibitor for the treatment of adults with progressing desmoid tumors who require systemic treatment, were published in the Journal of Clinical Oncology (JCO). The long-term follow-up data from DeFi, which was a global, randomized, multicenter, double-blind, placebo-controlled trial, were previously presented at the 2024 Connective Tissue Oncology Society Meeting. The new results published in JCO utilized a December 202

    10/21/25 2:00:13 AM ET
    $SWTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors

    STAMFORD, Conn., Aug. 18, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that the European Commission (EC) granted marketing authorization for OGSIVEO® (nirogacestat), an oral gamma secretase inhibitor, as monotherapy for the treatment of adults with progressing desmoid tumors who require systemic treatment. OGSIVEO is the first and only therapy approved in the European Union (EU) to treat desmoid tumors. "Desmoid tumors can have a profound impact on people's lives and are difficult to manage due to their invasive nature and high rates of recurrence. Until now, there have been no approved medicines in Europe

    8/18/25 9:10:52 AM ET
    $SWTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

    STAMFORD, Conn., July 18, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that the European Commission (EC) granted conditional marketing authorization for EZMEKLY® (mirdametinib) for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in pediatric and adult patients with neurofibromatosis type 1 (NF1) aged 2 years and above. EZMEKLY is the first and only therapy approved in the European Union (EU) for both adults and children with NF1-PN. "Patients with NF1-PN often face physical and mental health challenges and impaired quality of life given the limited treatment options available for this

    7/18/25 11:30:23 AM ET
    $SWTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SWTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evercore ISI initiated coverage on SpringWorks Therapeutics with a new price target

    Evercore ISI initiated coverage of SpringWorks Therapeutics with a rating of Outperform and set a new price target of $60.00

    11/20/24 8:20:27 AM ET
    $SWTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Guggenheim initiated coverage on SpringWorks Therapeutics with a new price target

    Guggenheim initiated coverage of SpringWorks Therapeutics with a rating of Buy and set a new price target of $75.00

    2/5/24 8:04:18 AM ET
    $SWTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BofA Securities initiated coverage on SpringWorks Therapeutics with a new price target

    BofA Securities initiated coverage of SpringWorks Therapeutics with a rating of Buy and set a new price target of $45.00

    12/1/22 7:57:05 AM ET
    $SWTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SWTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Edris Badreddin returned 169,712 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - SpringWorks Therapeutics, Inc. (0001773427) (Issuer)

    7/2/25 4:26:13 PM ET
    $SWTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Lynch Daniel returned 93,004 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - SpringWorks Therapeutics, Inc. (0001773427) (Issuer)

    7/2/25 4:25:44 PM ET
    $SWTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Lewis-Hall Freda C returned 24,727 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - SpringWorks Therapeutics, Inc. (0001773427) (Issuer)

    7/2/25 4:25:19 PM ET
    $SWTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SWTX
    Leadership Updates

    Live Leadership Updates

    View All

    SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directors

    STAMFORD, Conn., July 29, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced the appointment of Martin Mackay, Ph.D. to the Company's Board of Directors. Dr. Mackay is a highly accomplished research and development (R&D) executive with more than 30 years of pharmaceutical and biotech R&D experience, including leadership roles at Pfizer, AstraZeneca and Alexion. "Martin is a proven industry leader whose experience in developing and delivering novel treatments to patients in need is exceptional," said Saqib Islam, Chief Executive Officer of SpringWorks. "His expertise

    7/29/24 6:30:11 AM ET
    $SWTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer

    STAMFORD, Conn., Sept. 11, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced the appointment of Tai-An Lin, Ph.D., as its Chief Scientific Officer. Dr. Lin brings more than 25 years of biotechnology and global pharmaceutical experience in advancing drug discovery programs from target identification through early clinical trials across the therapeutic areas of oncology, immuno-oncology, and immunology. "Tai-An is a talented scientist with a strong track record of advancing innovative oncology programs from discovery

    9/11/23 6:30:00 AM ET
    $SWTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SpringWorks Therapeutics Appoints Carlos Albán to its Board of Directors

    STAMFORD, Conn., July 15, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced the appointment of Carlos Albán to the Company's Board of Directors. Mr. Albán, who served as Vice Chairman and Chief Commercial Officer at AbbVie, Inc. ("AbbVie") until his retirement last year, brings over 30 years of experience in global commercial strategy and operations. "Carlos' success in building and leading global commercial organizations will be valuable as SpringWorks continues its planned transition into a commercial-stage compa

    7/15/22 6:30:00 AM ET
    $SWTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SWTX
    Financials

    Live finance-specific insights

    View All

    SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

    – Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively – – Received FDA approval of GOMEKLI™ (mirdametinib) for the treatment of adult and pediatric patients with symptomatic NF1-PN not amendable to complete resection – – Ended 2024 with $461.9 million in cash, cash equivalents and marketable securities – STAMFORD, Conn., Feb. 20, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today reported financial results for the fourth quarter and full year periods ended December 31, 2024 and provi

    2/20/25 6:30:32 AM ET
    $SWTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SpringWorks Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 20, 2025

    STAMFORD, Conn., Jan. 30, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, February 20, 2025 to report its fourth quarter and full year financial results and discuss recent business updates. To join the live webcast and view the corresponding slides, please click here. To participate in the live conference call by phone, please click here to pre-register. Registered participants will then be provided with a dial-in number and conference code to access the call. A replay of the webcas

    1/30/25 7:00:50 AM ET
    $SWTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

    – Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter – – Long-term follow-up data from the Phase 3 DeFi trial of nirogacestat in adults with desmoid tumors highlight further reductions in tumor size, increase in ORR, sustained improvement in desmoid tumor symptoms, and consistent safety profile – – Granted FDA Priority Review on NDA and received validation of EU Marketing Authorization Application for mirdametinib for the treatment of adults and children with NF1-PN – – $498 million in cash, cash equivalents and marketable securities as of September 30, 2024; expected to fund the Company through profitability, which is anticipated in the first

    11/12/24 6:30:21 AM ET
    $SWTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SWTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by SpringWorks Therapeutics Inc.

    SC 13G/A - SpringWorks Therapeutics, Inc. (0001773427) (Subject)

    10/25/24 9:46:32 PM ET
    $SWTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by SpringWorks Therapeutics Inc. (Amendment)

    SC 13G/A - SpringWorks Therapeutics, Inc. (0001773427) (Subject)

    2/14/24 6:41:08 PM ET
    $SWTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by SpringWorks Therapeutics Inc. (Amendment)

    SC 13G/A - SpringWorks Therapeutics, Inc. (0001773427) (Subject)

    2/14/24 8:56:14 AM ET
    $SWTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care